Monday, May 30, 2016

Tuesday Features

Delivra implementing U.S. expansion strategy for topical creams

Delivra implementing U.S. expansion strategy for topical creams

Chris Schnarr, President & CFO The major initiative for Delivra (TSX-V:DVA) in 2016 is to introduce its flagship LivRelief topical pain and nerve creams to the U.S. market, initially through a U.S. web store and Amazon, and then through regional and national retailers, such as Walmart, Walgreens and CVS. “We are launching an aggressive digital... [Read more of this feature]


ARIAD hopes to launch second oncology drug in early 2017

ARIAD hopes to launch second oncology drug in early 2017

Tim Clackson, CSO ARIAD Pharmaceuticals (NASDAQ:ARIA) is hoping to receive FDA approval to commercialize in early 2017 its second orphan oncology product, brigatinib, for the treatment of certain genetic forms of non-small cell lung cancer. At the end of 2012, the company launched Iclusig (ponatinib) to treat patients with several genetic types of chronic... [Read more of this feature]


In conversation with Rosario G. Cartagena

In conversation with Rosario G. Cartagena

Rosario Cartagena As a member of the Health Law Group at Fasken Martineau in Toronto, Rosario Cartagena provides advice on a variety of health law matters, including corporate governance, public policy, government relations, risk management, privacy, health regulatory compliance, and health research. She also regularly assists in drafting agreements,... [Read more of this feature]


More Posts From Tuesday Features

Briefs

FDA approves Titan’s Probuphine implant for opioid dependence

FDA approves Titan’s Probuphine implant for opioid dependence

The FDA has approved Titan Pharmaceuticals’ (NASDAQ:TTNP) Probuphine implant, the first product for the long-term maintenance treatment of opioid dependence in clinically stable patients on 8 mg or less a day of oral buprenorphine. “Opioid abuse and addiction have taken a devastating toll on American families. We must do everything we can to... [Read more of this brief]


Nobilis Health strategy gains media attention

Nobilis Health strategy gains media attention

Nobilis Health (NYSE MKT:HLTH; TSX:NHC) VP of Corporate Development, Kolin Ozonian, has been interviewed by The Life Sciences Report about the company’s strategy of managing both acquisitions and internal growth at the same time. In the interview, Mr. Ozonian discusses how Nobilis is orchestrating the flow of new patients to its ambulatory surgical... [Read more of this brief]


BioSyent signs distribution pact for two CV products

BioSyent signs distribution pact for two CV products

BioSyent (TSX-V:RX; OTC:BIOYF) has signed an exclusive distribution agreement with a European partner for two new products in the cardiovascular therapeutic area for the Canadian market. The products have been approved in Europe and in certain other markets around the world and will be launched in Canada if approval is granted by Health Canada. BioSyent... [Read more of this brief]


Roth resumes coverage of Fibrocell at buy

Roth resumes coverage of Fibrocell at buy

Roth Capital Partners has resumed coverage of Fibrocell Science (NASDAQ:FCSC) with a “buy” rating and $7 price target. The stock closed at $2.12 on Monday. Fibrocell leverages its expertise with fibroblasts to target diseases of the skin, connective tissue and joints. The technology can take advantage of the inherent properties of fibroblasts,... [Read more of this brief]


Vital enrolls first subject in Phase 3 ELAD trial

Vital enrolls first subject in Phase 3 ELAD trial

Vital Therapies (NASDAQ:VTL) has enrolled the first subject in its Phase 3 trial designated, VTL-308, to evaluate the ELAD System in subjects with severe acute alcoholic hepatitis. ELAD is an extracorporeal human allogeneic cellular liver therapy. The trial is intended to enroll a minimum of 150 subjects, who will be randomized one-to-one to either... [Read more of this brief]


More Posts From Briefs
Email Newsletters with Constant Contact
Google+